



Sales, NI &amp; Operating CF, quarterly




DAP.DE / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation


Sales, NI &amp; Operating CF, quarterly




DHR-PA / Diagnostics &amp; Research / US / 2022-06-2




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation*


Sales, NI &amp; Operating CF, quarterly




LH / Diagnostics &amp; Research / US / 2022-08-02




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring


Sales, NI &amp; Operating CF, quarterly




LH / Diagnostics &amp; Research / US / 2022-08-02




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring


Sales, NI &amp; Operating CF, quarterly




ICLR / Diagnostics &amp; Research / IE / 2022-08-02




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly




*ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair*


Sales, NI &amp; Operating CF, quarterly




WAT / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly




Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers


Sales, NI &amp; Operating CF, quarterly




WAT / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly




Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers




Sales, NI &amp; Operating CF, quarterly




WAT / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers*




Sales, NI &amp; Operating CF, quarterly




CRL / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation


Sales, NI &amp; Operating CF, quarterly




CRL / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly



Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation


Sales, NI &amp; Operating CF, quarterly




EXAS / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid based tests. It has


Sales, NI &amp; Operating CF, quarterly




SHC / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.


Sales, NI &amp; Operating CF, quarterly




OCDX / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho


Sales, NI &amp; Operating CF, quarterly




MEDP / Diagnostics &amp; Research / US / 2022-07-27




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.


Sales, NI &amp; Operating CF, quarterly




MEDP / Diagnostics &amp; Research / US / 2022-07-27




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.




Sales, NI &amp; Operating CF, quarterly




LNTH / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; Technelite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57) a


Sales, NI &amp; Operating CF, quarterly




NTRA / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables


Sales, NI &amp; Operating CF, quarterly




VNRX / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.


Sales, NI &amp; Operating CF, quarterly




MYGN / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing*


Sales, NI &amp; Operating CF, quarterly




NEO / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly








Owners Earnings, annually



Inventory CF, quarterly




NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company




Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for *H. pylori* under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma


Sales, NI &amp; Operating CF, quarterly




FLGT / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction based tests, as well as antigen based*




Sales, NI &amp; Operating CF, quarterly




FLGT / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction based tests, as well as antigen based*


Sales, NI &amp; Operating CF, quarterly




AKU / 0 / 0 / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually




Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




ACRS / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TKX/JAK3 inhibitor as a potential treatment for T cell mediated autoimmune diseases; Gut Biased Program for inflammatory*


Sales, NI &amp; Operating CF, quarterly




ME / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly








Owners Earnings, annually








Inventory CF, quarterly



23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize promising drugs. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and




CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd cfDNA in blood; AlloSeq HCT, a solution for



CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd cfDNA in blood; AlloSeq HCT, a solution for


Sales, NI &amp; Operating CF, quarterly




RDNT / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.




Sales, NI &amp; Operating CF, quarterly




NOTV / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical

Sales, NI &amp; Operating CF, quarterly




BNGO / 0 / 0 / 2022-06-25



Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually




Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




CSTL / Diagnostics &amp; Research / US / 2022-08-11




Sales, NI &amp; Operating CF, annually



Price vs shares outstanding, quarterly




Owners Earnings, annually




Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company


Sales, NI &amp; Operating CF, quarterly




CSTL / Diagnostics &amp; Research / US / 2022-08-11




Sales, NI &amp; Operating CF, annually










Price vs shares outstanding, quarterly



Owners Earnings, annually




Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company




MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.


Sales, NI &amp; Operating CF, quarterly




FLDM / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 ELISA assays,


Sales, NI &amp; Operating CF, quarterly




BGLC / Diagnostics &amp; Research / MY / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management, primarily focusing on cardiovascular, diabetes, and cancer-related indications primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of cancers comprising nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon; bowel diseases, such as colitis and Crohn; and osteoarthritis. The company also wholesales industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Asia Pacific region. It markets its blood based genomic screening process to health care providers such as doctors, laboratories, and hospitals. BioNexus Gene Lab Corporation was




Sales, NI &amp; Operating CF, quarterly




AGL.L / Diagnostics &amp; Research / GB / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and HyCEAD multiplex analysis system used as the downstream analysis tool in the ovarian cancer clinical application. It also offers specialist circulating tumor cell enrichment and analysis services to support translational research studies and pharmaceutical trials. The company was founded in 1994 and is based in Guildford, the United Kingdom.


Sales, NI &amp; Operating CF, quarterly




ENZ / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological


Sales, NI &amp; Operating CF, quarterly




TTOO / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to


Sales, NI &amp; Operating CF, quarterly




TRIB / Diagnostics &amp; Research / IE / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme linked immunosorbent, western blot, and line immunoassay formats; and


Sales, NI &amp; Operating CF, quarterly




DRIO / Diagnostics &amp; Research / IL / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as


Sales, NI & Operating CF, quarterly



longTermDebt  
shortTermDebt  
cashAndCashEquivalents  
totalStockholdersEquity




Sales, NI & Operating CF, annually




44 %  
43 %  
42 %  
41 %  
40 %  
39 %  
38 %


Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, and the United States. The company's services cover histopathology reporting and human tissue testing services; genomics services to pharmaceuticals, biotechnology, life science, and academic markets; stability storage solutions; and COVID-19 antigen PCR testing services. It also manufactures reagents and kits for the blood group serology, blood banking, and tissue banking sectors; and engages in life science research activities, which cover antibodies, clones, cell culture reagents and assays, protein biology, laboratory essentials, and others. Sourcebio International Plc was incorporated in 2016 and is headquartered in Nottingham, the United Kingdom.


Sales, NI &amp; Operating CF, quarterly




AWH / 0 / 0 / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually



Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




DXRX.L / Diagnostics &amp; Research / GB / 2022-06-21




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Diaceutics PLC provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories, which provides lab mapping, testing dashboard, and physician mapping services. The company also provides DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics in a secure and standardized way. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics




Sales, NI &amp; Operating CF, quarterly




STIM / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.


Sales, NI &amp; Operating CF, quarterly




TOMDF / Diagnostics &amp; Research / IL / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tellovid, a 3CL protease inhibitor dietary supplement to


Sales, NI &amp; Operating CF, quarterly




CNTG / Diagnostics &amp; Research / DE / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers


Sales, NI &amp; Operating CF, quarterly




IDXG / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancreGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancreGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the


Sales, NI &amp; Operating CF, quarterly




APDN / Diagnostics &amp; Research / US / 2022-08-16




Sales, NI &amp; Operating CF, annually



Price vs shares outstanding, quarterly




Owners Earnings, annually




Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product


Sales, NI &amp; Operating CF, quarterly




APDN / Diagnostics &amp; Research / US / 2022-08-16




Sales, NI &amp; Operating CF, annually



Price vs shares outstanding, quarterly




Owners Earnings, annually




Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product


Sales, NI &amp; Operating CF, quarterly




STRR / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Construction, and Investments. It offers imaging services primarily to cardiologists, internal medicine physicians, and family practice doctors; and imaging systems, including nuclear cardiac and general purpose nuclear imaging systems to physician offices and hospitals. The company also develops, sells, and maintains solid-state gamma cameras; and provides camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity


Sales, NI &amp; Operating CF, quarterly




PMD / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law




Sales, NI &amp; Operating CF, quarterly




PRPO / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.


Sales, NI &amp; Operating CF, quarterly




HTGM / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers,


Sales, NI &amp; Operating CF, quarterly




AVCRF / Diagnostics &amp; Research / CA / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Avricore Health Inc. operates as a healthcare technology company in Canada. The company provides HealthTab, a lab-accurate point of care testing platform. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.


Sales, NI &amp; Operating CF, quarterly




SQL / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually



Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.


Sales, NI &amp; Operating CF, quarterly




SERA / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually



Price vs shares outstanding, quarterly








Owners Earnings, annually









Inventory CF, quarterly



Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.




ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.



ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.


Sales, NI &amp; Operating CF, quarterly




OPGN / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud based HIPAA compliant




Sales, NI &amp; Operating CF, quarterly




ABMC / 0 / 0 / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually




Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




BIOC / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly




Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies.


Sales, NI &amp; Operating CF, quarterly




GWHP / Diagnostics &amp; Research / US / 2022-06-2




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic test kits in the United States. The company offers rapid diagnostic tests, such as the CoVid-19 test, whole blood Ebola test, whole blood Zika test, whole blood rapid TB test, and various other tests for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, and other vector-borne diseases. Global WholeHealth Partners Corporation was incorporated in 2013 and is based in San Clemente, California.


Sales, NI &amp; Operating CF, quarterly




DIGP / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Digipath, Inc., together with its subsidiaries, provides cannabis and hemp lab testing services in Las Vegas to Nevada licensed medical marijuana enterprises. It also provides testing, cannabis education and training, and cannabis news coverage to the cannabis industry. The company operates as a testing laboratory facility for cannabis, cannabis infused products, hemp, and other botanical nutraceuticals to serve growers, dispensaries, caregivers, producers, patients, and end users of cannabis and botanical products. In addition, its labs screen medicinal and recreational cannabis for potentially harmful contaminants, including residual solvents; moisture; water activity; visual inspection; pesticides; heavy metals, such as mercury, arsenic, lead, cadmium, chromium, and nickel; biological toxins comprising aflatoxin and ocratoxins; and microbial contaminants consisting of E. coli, salmonella, coliforms, aspergillus, gram negative


Sales, NI &amp; Operating CF, quarterly




XGN / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually






Inventory CF, quarterly



Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it




## ISPC / Diagnostics & Research / US / 2022-06-25




iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Sales, NI &amp; Operating CF, quarterly




CEMI / 0 / 0 / 2022-06-24



Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually



Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




BNR / 0 / 0 / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly






Sales, NI &amp; Operating CF, quarterly




CO / 0 / 0 / 2022-06-24



Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually




Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




OPK / Diagnostics &amp; Research / US / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceutical businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective


Sales, NI &amp; Operating CF, quarterly




QGEN / Diagnostics &amp; Research / NL / 2022-06-24




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions;


Sales, NI &amp; Operating CF, quarterly




PKI / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and*


Sales, NI &amp; Operating CF, quarterly




PKI / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and*


Sales, NI &amp; Operating CF, quarterly




PKI / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly



*PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and*


Sales, NI &amp; Operating CF, quarterly




OLK / Diagnostics &amp; Research / SE / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose built software that enable users to import data, validate data quality, and normalize for


Sales, NI &amp; Operating CF, quarterly




GH / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early stage cancer patients;



Sales, NI &amp; Operating CF, quarterly




CHEK / 0 / 0 / 2022-06-25



Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly




Owners Earnings, annually




Inventory CF, quarterly




Sales, NI &amp; Operating CF, quarterly




GENE / Diagnostics &amp; Research / AU / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly






Owners Earnings, annually







Inventory CF, quarterly



Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing.




*DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to*




*DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to*


Sales, NI &amp; Operating CF, quarterly




TWST / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco.


Sales, NI &amp; Operating CF, quarterly




TWST / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco.


Sales, NI &amp; Operating CF, quarterly




IQV / Diagnostics &amp; Research / US / 2022-07-22




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and*


Sales, NI &amp; Operating CF, quarterly




IQV / Diagnostics &amp; Research / US / 2022-07-22




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and*




Sales, NI &amp; Operating CF, quarterly




TMO / Diagnostics &amp; Research / US / 2022-08-02




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready to use, and lyophilized immunodiagnostic reagent kits, as well as calibrators


Sales, NI &amp; Operating CF, quarterly




TMO / Diagnostics &amp; Research / US / 2022-08-02




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready to use, and lyophilized immunodiagnostic reagent kits, as well as calibrators


Sales, NI &amp; Operating CF, quarterly




BDSX / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



*Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix*


Sales, NI &amp; Operating CF, quarterly




BDSX / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix*


Sales, NI &amp; Operating CF, quarterly




GTH / Diagnostics &amp; Research / CN / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production scale sequencer. In addition, the company develops ctDNA lung cancer


Sales, NI &amp; Operating CF, quarterly




PSNL / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; Immunoid Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves


Sales, NI &amp; Operating CF, quarterly




PSNL / Diagnostics &amp; Research / US / 2022-08-07




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; Immunoid Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves


Sales, NI &amp; Operating CF, quarterly




NEOG / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors; seafood processors; fruit and




Sales, NI &amp; Operating CF, quarterly




NVTA / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly



Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.


Sales, NI &amp; Operating CF, quarterly




RNVA / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Rennova Health, Inc., together with its subsidiaries, provides health care services in the United States. As of December 31, 2021, it owns one operating hospital in Oneida, Tennessee; an acute care hospital and a physician's practice in Jamestown, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company was founded in 2005 and is based in West Palm Beach, Florida.*


Sales, NI &amp; Operating CF, quarterly




STRRP / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Star Equity Holdings, Inc. provides healthcare solutions in the United States and internationally. It operates through four segments: Diagnostic Services, Diagnostic Imaging, Construction, and Investments. It offers imaging services primarily to cardiologists, internal medicine physicians, and family practice doctors; and imaging systems, including nuclear cardiac and general purpose nuclear imaging systems to physician offices and hospitals. The company also develops, sells, and maintains solid-state gamma cameras; and provides camera maintenance contract services. In addition, it manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity


Sales, NI &amp; Operating CF, quarterly




ERF.PA / Diagnostics &amp; Research / LU / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various*


Sales, NI &amp; Operating CF, quarterly




NCYT.L / Diagnostics &amp; Research / FR / 2022-06-2




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Lab21 Products, IT-IS International, and Primerdesign segments. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The Primerdesign segment designs, manufactures, and markets molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and


Sales, NI &amp; Operating CF, quarterly




ILU.DE / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly




*Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe*


Sales, NI &amp; Operating CF, quarterly




MXCT.L / Diagnostics &amp; Research / US / 2022-06-25




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually




Inventory CF, quarterly



MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.


Sales, NI &amp; Operating CF, quarterly



ALECR.PA / Diagnostics &amp; Research / FR / 2022-06-




Sales, NI &amp; Operating CF, annually




Price vs shares outstanding, quarterly



Owners Earnings, annually



Inventory CF, quarterly



*Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.*